Bioatla Ownership
| BCAB Stock | USD 0.33 0.01 3.97% |
Bioatla |
Bioatla Stock Ownership Analysis
About 46.0% of the company shares are held by institutions such as insurance companies. The company has price-to-book (P/B) ratio of 0.86. Some equities with similar Price to Book (P/B) outperform the market in the long run. Bioatla recorded a loss per share of 1.7. The entity had not issued any dividends in recent years. BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California. Bioatla operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 56 people. For more info on Bioatla please contact Jay Short at 858 558 0708 or go to https://www.bioatla.com.Besides selling stocks to institutional investors, Bioatla also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Bioatla's stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Bioatla's strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Bioatla Quarterly Liabilities And Stockholders Equity |
|
About 8.0% of Bioatla are currently held by insiders. Unlike Bioatla's institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Bioatla's private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Bioatla's insider trades
Bioatla Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bioatla is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bioatla backward and forwards among themselves. Bioatla's institutional investor refers to the entity that pools money to purchase Bioatla's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Deutsche Bank Ag | 2024-12-31 | 525.4 K | Massachusetts Financial Services Company | 2024-12-31 | 515.8 K | Geode Capital Management, Llc | 2024-12-31 | 420 K | Norges Bank | 2024-12-31 | 389.1 K | Marshall Wace Asset Management Ltd | 2024-12-31 | 373.1 K | Gsa Capital Partners Llp | 2024-12-31 | 350.7 K | Susquehanna International Group, Llp | 2024-12-31 | 214.2 K | State Street Corp | 2024-12-31 | 151.4 K | Jane Street Group Llc | 2024-12-31 | 149.3 K | Anson Funds Management Lp | 2024-12-31 | 4.6 M | Highbridge Capital Management, Llc | 2024-12-31 | 2.5 M |
Bioatla Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bioatla insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bioatla's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bioatla insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Bioatla Outstanding Bonds
Bioatla issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bioatla uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bioatla bonds can be classified according to their maturity, which is the date when Bioatla has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Bioatla offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bioatla's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bioatla Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bioatla Stock:Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Bioatla. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation. For information on how to trade Bioatla Stock refer to our How to Trade Bioatla Stock guide.You can also try the Price Ceiling Movement module to calculate and plot Price Ceiling Movement for different equity instruments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bioatla. If investors know Bioatla will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bioatla listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.70) | Revenue Per Share | Quarterly Revenue Growth 0.316 | Return On Assets | Return On Equity |
The market value of Bioatla is measured differently than its book value, which is the value of Bioatla that is recorded on the company's balance sheet. Investors also form their own opinion of Bioatla's value that differs from its market value or its book value, called intrinsic value, which is Bioatla's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bioatla's market value can be influenced by many factors that don't directly affect Bioatla's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Bioatla's value and its price as these two are different measures arrived at by different means. Investors typically determine if Bioatla is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bioatla's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.